Illumina reports Q2 adjusted EPS $1.19, consensus $1.01

Reports Q2 revenue $1.06B, consensus $1.05B. “The Illumina (ILMN) team again delivered results that exceeded our guidance, driven by the continued ramp in X consumables, as well as accelerating growth in clinical, our largest customer segment,” said Jacob Thaysen, Chief Executive Officer. “In research, we are actively helping our customers navigate a constrained funding environment. Even in these challenging conditions, the team’s focus on operational excellence helped drive margin expansion, enabling us to increase our expectations for the year.”